Identification

Name
Arsenic trioxide
Accession Number
DB01169  (APRD00171)
Type
Small Molecule
Groups
Approved, Investigational
Description

Arsenic trioxide is a chemotheraputic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. Due to the toxic nature of arsenic, this drug carries significant health risks. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.

Structure
Thumb
Synonyms
  • Acide Arsenieux
  • Anhydride Arsenieux
  • Arsenic Blanc
  • Arsenic oxide
  • Arsenic(III) oxide
  • Arsenigen Saure
  • Arsenolite
  • Arsenous oxide
  • Arsenous oxide anhydride
  • Diarsenic oxide
  • Diarsenic trioxide
  • White arsenic
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TrisenoxSolution1 mgIntravenousLundbeck Inc.2013-09-09Not applicableCanada
TrisenoxInjection, solution1 mg/mLIntravenousCephalon2000-10-15Not applicableUs
Categories
UNII
S7V92P67HO
CAS number
1327-53-3
Weight
Average: 197.84
Monoisotopic: 197.827934
Chemical Formula
As2O3
InChI Key
IKWTVSLWAPBBKU-UHFFFAOYSA-N
InChI
InChI=1S/As2O3/c3-1-5-2-4
IUPAC Name
diarsorosooxidane
SMILES
O=[As]O[As]=O

Pharmacology

Indication

For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression

Structured Indications
Pharmacodynamics

Arsenic Trioxide is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy.

Mechanism of action

The mechanism of action of Arsenic Trioxide is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein PML/RAR-alpha. It is suspected that arsenic trioxide induces cancer cells to undergo apoptosis.

TargetActionsOrganism
AInhibitor of nuclear factor kappa-B kinase subunit beta
inducer
Human
AThioredoxin reductase 1, cytoplasmic
inhibitor
Human
ATranscription factor AP-1
inducer
Human
AG1/S-specific cyclin-D1
antagonist
Human
AMitogen-activated protein kinase 3
inducer
Human
AMitogen-activated protein kinase 1
inducer
Human
URAC-alpha serine/threonine-protein kinase
inducer
Human
UCyclin-dependent kinase inhibitor 1Not AvailableHuman
UHistone deacetylase 1Not AvailableHuman
UProtein PMLNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

75% bound

Metabolism

The metabolism of arsenic trioxide involves reduction of pentavalent arsenic to trivalent arsenic by arsenate reductase and methylation of trivalent arsenic to monomethylarsonic acid and monomethylarsonic acid to dimethylarsinic acid by methyltransferases. The main site of methylation reactions appears to be the liver. Arsenic is stored mainly in liver, kidney, heart, lung, hair and nails.

Route of elimination

Trivalent arsenic is mostly methylated in humans and excreted in urine.

Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of overdose include convulsions, muscle weakness and confusion.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Arsenic trioxide.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Acebutolol.Approved
AcetaminophenThe serum concentration of Arsenic trioxide can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Arsenic trioxide.Withdrawn
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Arsenic trioxide.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Arsenic trioxide.Experimental
AfatinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Afatinib.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Arsenic trioxide.Experimental
AlbendazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Aldesleukin.Approved
AldosteroneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Arsenic trioxide can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Arsenic trioxide.Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Arsenic trioxide.Approved
AmantadineAmantadine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Arsenic trioxide.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Amiloride.Approved
Aminohippuric acidThe serum concentration of Arsenic trioxide can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Arsenic trioxide.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Arsenic trioxide.Approved
AmlodipineThe serum concentration of Arsenic trioxide can be increased when it is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Arsenic trioxide.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Arsenic trioxide.Approved, Investigational
AmprenavirThe serum concentration of Arsenic trioxide can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Arsenic trioxide can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Amyl Nitrite.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Arsenic trioxide.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Apraclonidine.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Arsenic trioxide.Approved
ArtemetherArsenic trioxide may increase the QTc-prolonging activities of Artemether.Approved
AsenapineArsenic trioxide may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirAtazanavir may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
AtenololThe serum concentration of Arsenic trioxide can be increased when it is combined with Atenolol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Arsenic trioxide can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Azilsartan medoxomil.Approved
AzithromycinThe serum concentration of Arsenic trioxide can be increased when it is combined with Azithromycin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Arsenic trioxide.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Arsenic trioxide.Experimental
BarbitalBarbital may increase the hypotensive activities of Arsenic trioxide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Barnidipine.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Arsenic trioxide.Investigational
BedaquilineBedaquiline may increase the QTc-prolonging activities of Arsenic trioxide.Approved
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Arsenic trioxide.Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Bendroflumethiazide.Approved
BenzocaineThe serum concentration of Arsenic trioxide can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Arsenic trioxide can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Arsenic trioxide.Approved, Investigational
BiperidenThe serum concentration of Arsenic trioxide can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Bisoprolol.Approved
BoceprevirThe serum concentration of Arsenic trioxide can be increased when it is combined with Boceprevir.Withdrawn
BortezomibBortezomib may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
BosutinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Bosutinib.Approved
BretyliumThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Brimonidine.Approved
BromocriptineThe serum concentration of Arsenic trioxide can be increased when it is combined with Bromocriptine.Approved, Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Arsenic trioxide.Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Bupivacaine.Approved, Investigational
BuprenorphineThe serum concentration of Arsenic trioxide can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
BuspironeThe serum concentration of Arsenic trioxide can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Arsenic trioxide.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Arsenic trioxide.Approved
CaffeineThe serum concentration of Arsenic trioxide can be increased when it is combined with Caffeine.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Arsenic trioxide can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Arsenic trioxide can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Carbetocin.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Arsenic trioxide.Experimental
CarteololThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Carteolol.Approved
CarvedilolThe serum concentration of Arsenic trioxide can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Arsenic trioxide can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Arsenic trioxide.Experimental
CeritinibCeritinib may increase the QTc-prolonging activities of Arsenic trioxide.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Arsenic trioxide.Withdrawn
ChloroquineThe serum concentration of Arsenic trioxide can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Arsenic trioxide can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Arsenic trioxide can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Chlorthalidone.Approved
CholesterolThe serum concentration of Arsenic trioxide can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Arsenic trioxide can be decreased when it is combined with Cholic Acid.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Arsenic trioxide.Experimental
CilazaprilThe serum concentration of Arsenic trioxide can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Arsenic trioxide can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Arsenic trioxide can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Arsenic trioxide can be increased when it is combined with Clarithromycin.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Arsenic trioxide can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Clonidine.Approved
ClotrimazoleThe serum concentration of Arsenic trioxide can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Clozapine.Approved
CobicistatThe serum concentration of Arsenic trioxide can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Arsenic trioxide can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Arsenic trioxide can be increased when it is combined with Colforsin.Experimental
ConivaptanThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Arsenic trioxide.Approved, Investigational
CyclosporineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Arsenic trioxide.Experimental
DabrafenibDabrafenib may increase the QTc-prolonging activities of Arsenic trioxide.Approved
DaclatasvirThe serum concentration of Arsenic trioxide can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Arsenic trioxide can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Dapagliflozin.Approved
DasatinibDasatinib may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
DaunorubicinThe serum concentration of Arsenic trioxide can be decreased when it is combined with Daunorubicin.Approved
DegarelixDegarelix may increase the QTc-prolonging activities of Arsenic trioxide.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Arsenic trioxide.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Arsenic trioxide.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Arsenic trioxide.Approved
DesloratadineThe serum concentration of Arsenic trioxide can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe serum concentration of Arsenic trioxide can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Arsenic trioxide can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Diclofenamide.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Arsenic trioxide.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Arsenic trioxide.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Arsenic trioxide.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Arsenic trioxide.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Arsenic trioxide.Experimental
DihydroergotamineThe serum concentration of Arsenic trioxide can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Arsenic trioxide can be increased when it is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Dinutuximab.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
DipyridamoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Dipyridamole.Approved
DisopyramideDisopyramide may increase the QTc-prolonging activities of Arsenic trioxide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Arsenic trioxide.Approved, Investigational
DofetilideDofetilide may increase the QTc-prolonging activities of Arsenic trioxide.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Arsenic trioxide.Approved
DomperidoneArsenic trioxide may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Arsenic trioxide can be increased when it is combined with Doxazosin.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
DoxorubicinThe serum concentration of Arsenic trioxide can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Arsenic trioxide can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Arsenic trioxide can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Arsenic trioxide.Approved
DuloxetineArsenic trioxide may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Efonidipine.Approved
ElbasvirThe serum concentration of Arsenic trioxide can be increased when it is combined with Elbasvir.Approved
EliglustatArsenic trioxide may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Empagliflozin.Approved
EnalaprilThe serum concentration of Arsenic trioxide can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Enalaprilat.Approved
EnasidenibThe serum concentration of Arsenic trioxide can be increased when it is combined with Enasidenib.Approved
EnzalutamideThe serum concentration of Arsenic trioxide can be increased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Eprosartan.Approved
ErgonovineThe serum concentration of Arsenic trioxide can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Arsenic trioxide can be increased when it is combined with Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ErythromycinThe serum concentration of Arsenic trioxide can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramArsenic trioxide may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Esmolol.Approved
EstramustineThe serum concentration of Arsenic trioxide can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Arsenic trioxide can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Estrone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Etacrynic acid.Approved
EtoposideThe serum concentration of Arsenic trioxide can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Arsenic trioxide can be increased when it is combined with Etravirine.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Arsenic trioxide.Approved
FelodipineThe serum concentration of Arsenic trioxide can be increased when it is combined with Felodipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fenoldopam.Approved
FentanylThe serum concentration of Arsenic trioxide can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Arsenic trioxide can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Arsenic trioxide can be increased when it is combined with Fidaxomicin.Approved
FimasartanThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fimasartan.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Withdrawn
FluconazoleFluconazole may increase the QTc-prolonging activities of Arsenic trioxide.Approved
FluoxetineThe serum concentration of Arsenic trioxide can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Arsenic trioxide can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Arsenic trioxide can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Arsenic trioxide can be increased when it is combined with Flurazepam.Approved, Illicit
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Arsenic trioxide.Approved
FluvoxamineThe serum concentration of Arsenic trioxide can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Arsenic trioxide.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fosinopril.Approved
FurosemideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Furosemide.Approved, Vet Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Arsenic trioxide.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
GefitinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Gefitinib.Approved, Investigational
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
GenisteinThe serum concentration of Arsenic trioxide can be increased when it is combined with Genistein.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Arsenic trioxide.Experimental
GlecaprevirThe serum concentration of Arsenic trioxide can be increased when it is combined with Glecaprevir.Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Arsenic trioxide.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Arsenic trioxide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Arsenic trioxide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Arsenic trioxide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Arsenic trioxide.Approved
GlyburideThe serum concentration of Arsenic trioxide can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Arsenic trioxide can be increased when it is combined with Glycerin.Approved, Investigational
GoserelinGoserelin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
Gramicidin DThe serum concentration of Arsenic trioxide can be increased when it is combined with Gramicidin D.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
GrepafloxacinThe serum concentration of Arsenic trioxide can be increased when it is combined with Grepafloxacin.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Arsenic trioxide.Investigational
HaloperidolThe serum concentration of Arsenic trioxide can be increased when it is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Halothane.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Arsenic trioxide.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
HydralazineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Arsenic trioxide can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Hydroflumethiazide.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
IbutilideIbutilide may increase the QTc-prolonging activities of Arsenic trioxide.Approved
IdelalisibThe serum concentration of Arsenic trioxide can be increased when it is combined with Idelalisib.Approved
IloperidoneArsenic trioxide may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Iloprost.Approved, Investigational
ImatinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Imidapril.Investigational
ImipramineImipramine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Arsenic trioxide.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Arsenic trioxide.Approved
IndinavirThe serum concentration of Arsenic trioxide can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Arsenic trioxide can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Indoramin.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Arsenic trioxide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Arsenic trioxide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Arsenic trioxide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Arsenic trioxide.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Arsenic trioxide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Arsenic trioxide.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe serum concentration of Arsenic trioxide can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Isocarboxazid.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
ItraconazoleItraconazole may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
IvacaftorThe serum concentration of Arsenic trioxide can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Arsenic trioxide can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Arsenic trioxide can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Lacidipine.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Arsenic trioxide.Experimental
LansoprazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Arsenic trioxide.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Lercanidipine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Levobupivacaine.Approved
LevodopaArsenic trioxide may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Arsenic trioxide can be increased when it is combined with Levofloxacin.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Arsenic trioxide can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Arsenic trioxide.Approved
LiothyronineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Arsenic trioxide can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Arsenic trioxide.Approved
LisinoprilThe serum concentration of Arsenic trioxide can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Arsenic trioxide.Approved
LithiumLithium may increase the QTc-prolonging activities of Arsenic trioxide.Approved
LofexidineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Arsenic trioxide can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Arsenic trioxide can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Arsenic trioxide can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Arsenic trioxide can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Arsenic trioxide can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Arsenic trioxide can be increased when it is combined with Lovastatin.Approved, Investigational
LumacaftorThe serum concentration of Arsenic trioxide can be decreased when it is combined with Lumacaftor.Approved
LumefantrineArsenic trioxide may increase the QTc-prolonging activities of Lumefantrine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Arsenic trioxide.Illicit, Withdrawn
MannitolThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Mannitol.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Arsenic trioxide.Approved
MebendazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Mecamylamine.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
Megestrol acetateThe serum concentration of Arsenic trioxide can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Arsenic trioxide can be increased when it is combined with Meprobamate.Approved, Illicit
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Arsenic trioxide.Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Arsenic trioxide.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Arsenic trioxide.Approved
MethadoneThe serum concentration of Arsenic trioxide can be increased when it is combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Arsenic trioxide.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Methyldopa.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Arsenic trioxide.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Arsenic trioxide.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Arsenic trioxide.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Arsenic trioxide.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Metipranolol.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Metolazone.Approved
MetoprololThe serum concentration of Arsenic trioxide can be increased when it is combined with Metoprolol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Arsenic trioxide.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Arsenic trioxide.Experimental
MibefradilThe serum concentration of Arsenic trioxide can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Arsenic trioxide can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Arsenic trioxide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Arsenic trioxide.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Minoxidil.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Arsenic trioxide.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
MitomycinThe serum concentration of Arsenic trioxide can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Arsenic trioxide.Approved
MorphineThe serum concentration of Arsenic trioxide can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nadolol.Approved
NaltrexoneThe serum concentration of Arsenic trioxide can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Arsenic trioxide can be increased when it is combined with Naringenin.Experimental
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirNelfinavir may increase the QTc-prolonging activities of Arsenic trioxide.Approved
NeostigmineThe serum concentration of Arsenic trioxide can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nesiritide.Approved, Investigational
NicardipineNicardipine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Arsenic trioxide.Approved
NicorandilNicorandil may increase the hypotensive activities of Arsenic trioxide.Approved
NifedipineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nimodipine.Approved
NisoldipineThe serum concentration of Arsenic trioxide can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Arsenic trioxide can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Arsenic trioxide can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nitroprusside.Approved
NorethisteroneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Arsenic trioxide.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Obinutuzumab.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Arsenic trioxide.Experimental
OlmesartanThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Olmesartan.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Arsenic trioxide.Approved
OmeprazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Arsenic trioxide.Approved
OuabainOuabain may decrease the cardiotoxic activities of Arsenic trioxide.Approved
OxprenololThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Oxprenolol.Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
P-NitrophenolThe serum concentration of Arsenic trioxide can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Arsenic trioxide.Approved, Vet Approved
PaliperidoneArsenic trioxide may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Arsenic trioxide can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatPanobinostat may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
PantoprazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Papaverine.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Arsenic trioxide.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Arsenic trioxide.Approved
PenbutololThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Penbutolol.Approved, Investigational
PentamidinePentamidine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Arsenic trioxide.Approved, Vet Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Arsenic trioxide.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Arsenic trioxide.Approved, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Arsenic trioxide can be increased when it is combined with Perindopril.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Arsenic trioxide.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Phenelzine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Arsenic trioxide.Approved, Withdrawn
PhenobarbitalThe serum concentration of Arsenic trioxide can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Phentolamine.Approved
PibrentasvirThe serum concentration of Arsenic trioxide can be increased when it is combined with Pibrentasvir.Approved
PimozideThe serum concentration of Arsenic trioxide can be increased when it is combined with Pimozide.Approved
PindololThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Pipamperone.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Arsenic trioxide.Approved
Platelet Activating FactorThe serum concentration of Arsenic trioxide can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Ponatinib.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
PravastatinThe serum concentration of Arsenic trioxide can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Arsenic trioxide can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Arsenic trioxide can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
PrimidonePrimidone may increase the hypotensive activities of Arsenic trioxide.Approved, Vet Approved
ProbenecidThe serum concentration of Arsenic trioxide can be increased when it is combined with Probenecid.Approved
ProcainamideProcainamide may increase the QTc-prolonging activities of Arsenic trioxide.Approved
ProgesteroneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
PropafenoneThe serum concentration of Arsenic trioxide can be increased when it is combined with Propafenone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Arsenic trioxide can be increased when it is combined with Propranolol.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Arsenic trioxide.Experimental
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Arsenic trioxide.Approved
QuercetinThe serum concentration of Arsenic trioxide can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Arsenic trioxide can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Arsenic trioxide can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Arsenic trioxide can be increased when it is combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ramipril.Approved
RanitidineThe serum concentration of Arsenic trioxide can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Arsenic trioxide can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Rasagiline.Approved
ReboxetineThe serum concentration of Arsenic trioxide can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Arsenic trioxide can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Remifentanil.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ReserpineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Reserpine.Approved
RifampicinThe serum concentration of Arsenic trioxide can be decreased when it is combined with Rifampicin.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
RiociguatThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Riociguat.Approved
RisperidoneArsenic trioxide may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
RolapitantThe serum concentration of Arsenic trioxide can be increased when it is combined with Rolapitant.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Arsenic trioxide.Approved
RotigotineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sacubitril.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Arsenic trioxide.Approved
SaquinavirThe serum concentration of Arsenic trioxide can be decreased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Arsenic trioxide.Approved
ScopolamineThe serum concentration of Arsenic trioxide can be increased when it is combined with Scopolamine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Arsenic trioxide.Approved, Vet Approved
SelegilineThe serum concentration of Arsenic trioxide can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineSertraline may increase the QTc-prolonging activities of Arsenic trioxide.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
SimeprevirThe serum concentration of Arsenic trioxide can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Arsenic trioxide can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Arsenic trioxide can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sodium Nitrite.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Arsenic trioxide.Investigational
SotalolThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sotalol.Approved
SpironolactoneThe serum concentration of Arsenic trioxide can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Arsenic trioxide can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Arsenic trioxide can be increased when it is combined with Staurosporine.Experimental
StreptokinaseThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Arsenic trioxide can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sufentanil.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Arsenic trioxide.Approved
SulfinpyrazoneThe serum concentration of Arsenic trioxide can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
SumatriptanThe serum concentration of Arsenic trioxide can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
TacrineThe serum concentration of Arsenic trioxide can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Arsenic trioxide can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Arsenic trioxide.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tamsulosin.Approved, Investigational
Taurocholic AcidThe serum concentration of Arsenic trioxide can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Arsenic trioxide can be increased when it is combined with Telaprevir.Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
TelmisartanThe serum concentration of Arsenic trioxide can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Arsenic trioxide can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Arsenic trioxide can be increased when it is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Arsenic trioxide.Approved
TerfenadineThe serum concentration of Arsenic trioxide can be increased when it is combined with Terfenadine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Arsenic trioxide.Experimental
TesmilifeneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Arsenic trioxide can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineArsenic trioxide may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Arsenic trioxide.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Arsenic trioxide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Thioridazine.Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Arsenic trioxide.Approved
TicagrelorThe serum concentration of Arsenic trioxide can be increased when it is combined with Ticagrelor.Approved
TimololThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Timolol.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Arsenic trioxide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Arsenic trioxide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
TolvaptanThe serum concentration of Arsenic trioxide can be increased when it is combined with Tolvaptan.Approved
TorasemideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Torasemide.Approved
ToremifeneToremifene may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Arsenic trioxide.Approved, Investigational
TrazodoneTrazodone may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Triamterene.Approved
TrifluoperazineThe serum concentration of Arsenic trioxide can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Arsenic trioxide can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Arsenic trioxide.Withdrawn
TroleandomycinThe serum concentration of Arsenic trioxide can be increased when it is combined with Troleandomycin.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Arsenic trioxide.Experimental
ValsartanThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Valsartan.Approved, Investigational
VandetanibArsenic trioxide may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Arsenic trioxide.Approved
VelpatasvirThe serum concentration of Arsenic trioxide can be increased when it is combined with Velpatasvir.Approved
VemurafenibArsenic trioxide may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
VerapamilThe serum concentration of Arsenic trioxide can be decreased when it is combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Arsenic trioxide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
VinblastineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Arsenic trioxide can be increased when it is combined with Vinorelbine.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
VoxilaprevirThe serum concentration of Arsenic trioxide can be increased when it is combined with Voxilaprevir.Approved
ZimelidineThe serum concentration of Arsenic trioxide can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Arsenic trioxide.Approved
ZuclopenthixolArsenic trioxide may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
  1. Lu J, Chew EH, Holmgren A: Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12288-93. Epub 2007 Jul 18. [PubMed:17640917]
External Links
KEGG Drug
D02106
ChemSpider
229103
ChEMBL
CHEMBL1200978
Therapeutic Targets Database
DNC000255
PharmGKB
PA448486
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Arsenic_trioxide
ATC Codes
L01XX27 — Arsenic trioxide
AHFS Codes
  • 92:02.00*
PDB Entries
Not Available
FDA label
Download (46.3 KB)
MSDS
Download (78.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentAgnogenic Myeloid Metaplasia1
1Active Not RecruitingTreatmentChronic Myelogenous Leukemia (CML)1
1CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma1
1CompletedTreatmentBrain Cancer1
1CompletedTreatmentBrain and Central Nervous System Tumors2
1CompletedTreatmentColorectal Cancers1
1CompletedTreatmentLeukemias1
1CompletedTreatmentLeukemias / Malignant Lymphomas1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
1CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1CompletedTreatmentMyelodysplastic Syndromes and Leukemia, Myeloid, Acute1
1CompletedTreatmentRefractory Multiple Myeloma / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
1RecruitingTreatmentAdvanced Hematological Disorders1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1TerminatedTreatmentAcute Promyelocytic Leukemia (APL)1
1TerminatedTreatmentEssential Thrombocythemia (ET) / Polycythemia Vera (PV) / Primary Myelofibrosis1
1TerminatedTreatmentLeukemias / Myelodysplastic Syndromes1
1WithdrawnTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors1
1, 2CompletedTreatmentLeukemias3
1, 2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1, 2CompletedTreatmentMultiple Myeloma (MM) / Transplantation, Stem Cell1
1, 2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2CompletedTreatmentMyelodysplastic Syndrome1
1, 2CompletedTreatmentPlasma Cell Myeloma1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2TerminatedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
1, 2TerminatedTreatmentMetastatic Melanoma1
2Active Not RecruitingTreatmentAcute Promyelocytic Leukemia (APL)1
2Active Not RecruitingTreatmentLeukemias1
2CompletedTreatmentAcute Promyelocytic Leukemia (APL)1
2CompletedTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Childhood Germ Cell Tumor / Extragonadal Germ Cell Tumor / Liver Cancer / Neuroblastomas / Renal Cancers / Retinoblastoma / Sarcomas1
2CompletedTreatmentCancer Other Than Leukemia1
2CompletedTreatmentCancers / Leukemia, Other1
2CompletedTreatmentCarcinoma, Small Cell / Lung Cancers / Lung neoplasm malignant / Pulmonary Cancer / Pulmonary Neoplasms1
2CompletedTreatmentCervical Cancers1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentExtragonadal Germ Cell Tumor / Testicular germ cell tumour1
2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2CompletedTreatmentLeukemias6
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes2
2CompletedTreatmentLiver Cancer1
2CompletedTreatmentLung Cancers1
2CompletedTreatmentMalignant Lymphomas1
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentMultiple Myeloma (MM)2
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentRecurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Urethral Cancer / Transitional Cell Carcinoma of the Bladder / Ureteral Cancer1
2CompletedTreatmentRenal Cancers1
2Not Yet RecruitingTreatmentPrimary Hepatocellular Carcinoma1
2RecruitingTreatmentChronic Graft Versus Host Disease / Immune System Diseases1
2RecruitingTreatmentChronic Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
2RecruitingTreatmentLeukemias1
2TerminatedNot AvailableMyelodysplastic Syndromes (MDS)1
2TerminatedTreatmentAcute Myelogenous Leukaemia (AML)1
2TerminatedTreatmentAdenocarcinoma of the Esophagus / Stage III Esophageal Cancer / Stage IV Esophageal Cancer1
2TerminatedTreatmentEndometrial Carcinoma1
2TerminatedTreatmentHepatocellular,Carcinoma1
2TerminatedTreatmentLeukemias2
2TerminatedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2TerminatedTreatmentMalignant Lymphomas1
2TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2TerminatedTreatmentMyelodysplastic Syndrome1
2TerminatedTreatmentSystemic Lupus1
2Unknown StatusTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2Unknown StatusTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
2WithdrawnTreatmentAcute Promyelocytic Leukemia (APL)1
2WithdrawnTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
2WithdrawnTreatmentCancer, Breast1
2WithdrawnTreatmentLeukemias2
2WithdrawnTreatmentRefractory Plasma Cell Neoplasm / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2WithdrawnTreatmentRefractory Plasma Cell Neoplasm / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2, 3CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
2, 3Unknown StatusTreatmentHepatocellular,Carcinoma1
3Active Not RecruitingTreatmentChildhood Acute Promyelocytic Leukemia (M3) / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3Active Not RecruitingTreatmentLeukemias1
3CompletedTreatmentAdult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Promyelocytic Leukemia (M3) / Childhood Acute Promyelocytic Leukemia (M3) / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3RecruitingTreatmentAcute Promyelocytic Leukemia (APL)2
3RecruitingTreatmentAdult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Childhood Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Myeloid Neoplasm1
3TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
4CompletedTreatmentAcute Promyelocytic Leukemia (APL)1
4Enrolling by InvitationTreatmentChildhood Acute Promyelocytic Leukemia1
4Unknown StatusTreatmentRefractory Acute Promyelocytic Leukemia / Relapsed Acute Promyelocytic Leukemia1
Not AvailableCompletedBasic ScienceBasal Cell Carcinoma of the Skin / Recurrent Skin Cancer1
Not AvailableNot Yet RecruitingTreatmentSkin Basal Cell Carcinoma1
Not AvailableTerminatedTreatmentExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Leukemia, Prolymphocytic / Nodal marginal zone B-cell lymphomas / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous1 mg/mL
SolutionIntravenous1 mg
Prices
Unit descriptionCostUnit
Trisenox 10 mg/10 ml ampule43.58USD ml
Arsenic trioxide powder2.59USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6723351No1998-11-102018-11-10Us
US6855339No1998-11-102018-11-10Us
US6861076No1998-11-102018-11-10Us
US6884439No1998-11-102018-11-10Us
US6982096No1998-11-102018-11-10Us
US8273379No1998-11-102018-11-10Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility1.7E+004 mg/L (at 16 °C)SHIU,WY ET AL. (1990)
Predicted Properties
PropertyValueSource
logP1.07ChemAxon
pKa (Strongest Basic)-6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area43.37 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity4.24 m3·mol-1ChemAxon
Polarizability6.91 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9839
Blood Brain Barrier+0.9549
Caco-2 permeable-0.526
P-glycoprotein substrateNon-substrate0.8227
P-glycoprotein inhibitor INon-inhibitor0.9138
P-glycoprotein inhibitor IINon-inhibitor0.9925
Renal organic cation transporterNon-inhibitor0.9297
CYP450 2C9 substrateNon-substrate0.9036
CYP450 2D6 substrateNon-substrate0.829
CYP450 3A4 substrateNon-substrate0.7462
CYP450 1A2 substrateNon-inhibitor0.7393
CYP450 2C9 inhibitorNon-inhibitor0.8625
CYP450 2D6 inhibitorNon-inhibitor0.9133
CYP450 2C19 inhibitorNon-inhibitor0.7968
CYP450 3A4 inhibitorNon-inhibitor0.9567
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9743
Ames testNon AMES toxic0.5978
CarcinogenicityNon-carcinogens0.5984
BiodegradationReady biodegradable0.8156
Rat acute toxicity2.5942 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8253
hERG inhibition (predictor II)Non-inhibitor0.9812
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as metalloid oxides. These are inorganic compounds containing an oxygen atom of an oxidation state of -2, in which the heaviest atom bonded to the oxygen is a metalloid.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Metalloid organides
Sub Class
Metalloid oxides
Direct Parent
Metalloid oxides
Alternative Parents
Metalloid salts / Inorganic oxides / Inorganic arsenic compounds
Substituents
Metalloid oxide / Inorganic oxide / Inorganic metalloid salt / Inorganic arsenic compound
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inducer
General Function
Scaffold protein binding
Specific Function
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or oth...
Gene Name
IKBKB
Uniprot ID
O14920
Uniprot Name
Inhibitor of nuclear factor kappa-B kinase subunit beta
Molecular Weight
86563.245 Da
References
  1. Ouyang W, Ma Q, Li J, Zhang D, Liu ZG, Rustgi AK, Huang C: Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res. 2005 Oct 15;65(20):9287-93. [PubMed:16230390]
  2. Ouyang W, Li J, Ma Q, Huang C: Essential roles of PI-3K/Akt/IKKbeta/NFkappaB pathway in cyclin D1 induction by arsenite in JB6 Cl41 cells. Carcinogenesis. 2006 Apr;27(4):864-73. Epub 2005 Dec 29. [PubMed:16387740]
  3. Ouyang W, Zhang D, Ma Q, Li J, Huang C: Cyclooxygenase-2 induction by arsenite through the IKKbeta/NFkappaB pathway exerts an antiapoptotic effect in mouse epidermal Cl41 cells. Environ Health Perspect. 2007 Apr;115(4):513-8. Epub 2006 Dec 14. [PubMed:17450217]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Thioredoxin-disulfide reductase activity
Specific Function
Isoform 1 may possess glutaredoxin activity as well as thioredoxin reductase activity and induces actin and tubulin polymerization, leading to formation of cell membrane protrusions. Isoform 4 enha...
Gene Name
TXNRD1
Uniprot ID
Q16881
Uniprot Name
Thioredoxin reductase 1, cytoplasmic
Molecular Weight
70905.58 Da
References
  1. Lu J, Chew EH, Holmgren A: Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12288-93. Epub 2007 Jul 18. [PubMed:17640917]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inducer
General Function
Transcriptional activator activity, rna polymerase ii transcription factor binding
Specific Function
Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expre...
Gene Name
JUN
Uniprot ID
P05412
Uniprot Name
Transcription factor AP-1
Molecular Weight
35675.32 Da
References
  1. Muscarella DE, Bloom SE: Differential activation of the c-Jun N-terminal kinase pathway in arsenite-induced apoptosis and sensitization of chemically resistant compared to susceptible B-lymphoma cell lines. Toxicol Sci. 2002 Jul;68(1):82-92. [PubMed:12075113]
  2. Dong Z: The molecular mechanisms of arsenic-induced cell transformation and apoptosis. Environ Health Perspect. 2002 Oct;110 Suppl 5:757-9. [PubMed:12426127]
  3. Drobna Z, Jaspers I, Thomas DJ, Styblo M: Differential activation of AP-1 in human bladder epithelial cells by inorganic and methylated arsenicals. FASEB J. 2003 Jan;17(1):67-9. Epub 2002 Nov 15. [PubMed:12475910]
  4. Li J, Gorospe M, Barnes J, Liu Y: Tumor promoter arsenite stimulates histone H3 phosphoacetylation of proto-oncogenes c-fos and c-jun chromatin in human diploid fibroblasts. J Biol Chem. 2003 Apr 11;278(15):13183-91. Epub 2003 Jan 23. [PubMed:12547826]
  5. Kietzmann T, Samoylenko A, Immenschuh S: Transcriptional regulation of heme oxygenase-1 gene expression by MAP kinases of the JNK and p38 pathways in primary cultures of rat hepatocytes. J Biol Chem. 2003 May 16;278(20):17927-36. Epub 2003 Mar 11. [PubMed:12637567]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Transcription factor binding
Specific Function
Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S t...
Gene Name
CCND1
Uniprot ID
P24385
Uniprot Name
G1/S-specific cyclin-D1
Molecular Weight
33728.74 Da
References
  1. Hyun Park W, Hee Cho Y, Won Jung C, Oh Park J, Kim K, Hyuck Im Y, Lee MH, Ki Kang W, Park K: Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun. 2003 Jan 3;300(1):230-5. [PubMed:12480548]
  2. Ouyang W, Ma Q, Li J, Zhang D, Liu ZG, Rustgi AK, Huang C: Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res. 2005 Oct 15;65(20):9287-93. [PubMed:16230390]
  3. Ouyang W, Li J, Ma Q, Huang C: Essential roles of PI-3K/Akt/IKKbeta/NFkappaB pathway in cyclin D1 induction by arsenite in JB6 Cl41 cells. Carcinogenesis. 2006 Apr;27(4):864-73. Epub 2005 Dec 29. [PubMed:16387740]
  4. Hwang BJ, Utti C, Steinberg M: Induction of cyclin D1 by submicromolar concentrations of arsenite in human epidermal keratinocytes. Toxicol Appl Pharmacol. 2006 Dec 1;217(2):161-7. Epub 2006 Aug 11. [PubMed:17005224]
  5. Ouyang W, Li J, Zhang D, Jiang BH, Huang DC: PI-3K/Akt signal pathway plays a crucial role in arsenite-induced cell proliferation of human keratinocytes through induction of cyclin D1. J Cell Biochem. 2007 Jul 1;101(4):969-78. [PubMed:17370311]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inducer
General Function
Phosphatase binding
Specific Function
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK ca...
Gene Name
MAPK3
Uniprot ID
P27361
Uniprot Name
Mitogen-activated protein kinase 3
Molecular Weight
43135.16 Da
References
  1. Fauconneau B, Petegnief V, Sanfeliu C, Piriou A, Planas AM: Induction of heat shock proteins (HSPs) by sodium arsenite in cultured astrocytes and reduction of hydrogen peroxide-induced cell death. J Neurochem. 2002 Dec;83(6):1338-48. [PubMed:12472888]
  2. Jung DK, Bae GU, Kim YK, Han SH, Choi WS, Kang H, Seo DW, Lee HY, Cho EJ, Lee HW, Han JW: Hydrogen peroxide mediates arsenite activation of p70(s6k) and extracellular signal-regulated kinase. Exp Cell Res. 2003 Oct 15;290(1):144-54. [PubMed:14516795]
  3. Tanaka-Kagawa T, Hanioka N, Yoshida H, Jinno H, Ando M: Arsenite and arsenate activate extracellular signal-regulated kinases 1/2 by an epidermal growth factor receptor-mediated pathway in normal human keratinocytes. Br J Dermatol. 2003 Dec;149(6):1116-27. [PubMed:14674888]
  4. Felix K, Manna SK, Wise K, Barr J, Ramesh GT: Low levels of arsenite activates nuclear factor-kappaB and activator protein-1 in immortalized mesencephalic cells. J Biochem Mol Toxicol. 2005;19(2):67-77. [PubMed:15849723]
  5. Mousa SA, O'Connor L, Rossman TG, Block E: Pro-angiogenesis action of arsenic and its reversal by selenium-derived compounds. Carcinogenesis. 2007 May;28(5):962-7. Epub 2006 Dec 8. [PubMed:17158527]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inducer
General Function
Rna polymerase ii carboxy-terminal domain kinase activity
Specific Function
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK ca...
Gene Name
MAPK1
Uniprot ID
P28482
Uniprot Name
Mitogen-activated protein kinase 1
Molecular Weight
41389.265 Da
References
  1. Dong Z: The molecular mechanisms of arsenic-induced cell transformation and apoptosis. Environ Health Perspect. 2002 Oct;110 Suppl 5:757-9. [PubMed:12426127]
  2. He Z, Ma WY, Liu G, Zhang Y, Bode AM, Dong Z: Arsenite-induced phosphorylation of histone H3 at serine 10 is mediated by Akt1, extracellular signal-regulated kinase 2, and p90 ribosomal S6 kinase 2 but not mitogen- and stress-activated protein kinase 1. J Biol Chem. 2003 Mar 21;278(12):10588-93. Epub 2003 Jan 14. [PubMed:12529330]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Protein serine/threonine/tyrosine kinase activity
Specific Function
AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, ...
Gene Name
AKT1
Uniprot ID
P31749
Uniprot Name
RAC-alpha serine/threonine-protein kinase
Molecular Weight
55686.035 Da
References
  1. Fauconneau B, Petegnief V, Sanfeliu C, Piriou A, Planas AM: Induction of heat shock proteins (HSPs) by sodium arsenite in cultured astrocytes and reduction of hydrogen peroxide-induced cell death. J Neurochem. 2002 Dec;83(6):1338-48. [PubMed:12472888]
  2. He Z, Ma WY, Liu G, Zhang Y, Bode AM, Dong Z: Arsenite-induced phosphorylation of histone H3 at serine 10 is mediated by Akt1, extracellular signal-regulated kinase 2, and p90 ribosomal S6 kinase 2 but not mitogen- and stress-activated protein kinase 1. J Biol Chem. 2003 Mar 21;278(12):10588-93. Epub 2003 Jan 14. [PubMed:12529330]
  3. Ivanov VN, Hei TK: Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway. Oncogene. 2005 Jan 20;24(4):616-26. [PubMed:15580309]
  4. Wang ZX, Jiang CS, Liu L, Wang XH, Jin HJ, Wu Q, Chen Q: The role of Akt on arsenic trioxide suppression of 3T3-L1 preadipocyte differentiation. Cell Res. 2005 May;15(5):379-86. [PubMed:15916724]
  5. Tsou TC, Tsai FY, Hsieh YW, Li LA, Yeh SC, Chang LW: Arsenite induces endothelial cytotoxicity by down-regulation of vascular endothelial nitric oxide synthase. Toxicol Appl Pharmacol. 2005 Nov 1;208(3):277-84. [PubMed:16239170]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
May be involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localization and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex. Inhibits DNA synthesis by DNA polymerase delta by competing with POLD3 for PCNA binding (PubMed:11595739).
Specific Function
Cyclin binding
Gene Name
CDKN1A
Uniprot ID
P38936
Uniprot Name
Cyclin-dependent kinase inhibitor 1
Molecular Weight
18119.145 Da
References
  1. Huang HS, Liu ZM, Hong DY: Blockage of JNK pathway enhances arsenic trioxide-induced apoptosis in human keratinocytes. Toxicol Appl Pharmacol. 2010 Apr 15;244(2):234-41. doi: 10.1016/j.taap.2009.12.037. Epub 2010 Jan 11. [PubMed:20074581]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transcription regulatory region sequence-specific dna binding
Specific Function
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
Gene Name
HDAC1
Uniprot ID
Q13547
Uniprot Name
Histone deacetylase 1
Molecular Weight
55102.615 Da
References
  1. Huang HS, Liu ZM, Hong DY: Blockage of JNK pathway enhances arsenic trioxide-induced apoptosis in human keratinocytes. Toxicol Appl Pharmacol. 2010 Apr 15;244(2):234-41. doi: 10.1016/j.taap.2009.12.037. Epub 2010 Jan 11. [PubMed:20074581]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Functions via its association with PML-nuclear bodies (PML-NBs) in a wide range of important cellular processes, including tumor suppression, transcriptional regulation, apoptosis, senescence, DNA damage response, and viral defense mechanisms. Acts as the scaffold of PML-NBs allowing other proteins to shuttle in and out, a process which is regulated by SUMO-mediated modifications and interactions. Isoform PML-4 has a multifaceted role in the regulation of apoptosis and growth suppression: activates RB1 and inhibits AKT1 via interactions with PP1 and PP2A phosphatases respectively, negatively affects the PI3K pathway by inhibiting MTOR and activating PTEN, and positively regulates p53/TP53 by acting at different levels (by promoting its acetylation and phosphorylation and by inhibiting its MDM2-dependent degradation). Isoform PML-4 also: acts as a transcriptional repressor of TBX2 during cellular senescence and the repression is dependent on a functional RBL2/E2F4 repressor complex, regulates double-strand break repair in gamma-irradiation-induced DNA damage responses via its interaction with WRN, acts as a negative regulator of telomerase by interacting with TERT, and regulates PER2 nuclear localization and circadian function. Isoform PML-6 inhibits specifically the activity of the tetrameric form of PKM. The nuclear isoforms (isoform PML-1, isoform PML-2, isoform PML-3, isoform PML-4 and isoform PML-5) in concert with SATB1 are involved in local chromatin-loop remodeling and gene expression regulation at the MHC-I locus. Isoform PML-2 is required for efficient IFN-gamma induced MHC II gene transcription via regulation of CIITA. Cytoplasmic PML is involved in the regulation of the TGF-beta signaling pathway. PML also regulates transcription activity of ELF4 and can act as an important mediator for TNF-alpha- and IFN-alpha-mediated inhibition of endothelial cell network formation and migration.
Specific Function
Cobalt ion binding
Gene Name
PML
Uniprot ID
P29590
Uniprot Name
Protein PML
Molecular Weight
97549.475 Da
References
  1. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M, Zhang QY, Yang HY, Huang QH, Zhou GB, Tong JH, Zhang Y, Wu JH, Hu HY, de The H, Chen SJ, Chen Z: Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science. 2010 Apr 9;328(5975):240-3. doi: 10.1126/science.1183424. [PubMed:20378816]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1B1
Uniprot ID
Q16678
Uniprot Name
Cytochrome P450 1B1
Molecular Weight
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Shooshtary S, Behtash S, Nafisi S: Arsenic trioxide binding to serum proteins. J Photochem Photobiol B. 2015 Jul;148:31-36. doi: 10.1016/j.jphotobiol.2015.03.001. Epub 2015 Apr 1. [PubMed:25863441]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Kauffmann HM, Pfannschmidt S, Zoller H, Benz A, Vorderstemann B, Webster JI, Schrenk D: Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology. 2002 Feb 28;171(2-3):137-46. [PubMed:11836020]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Hu XM, Hirano T, Oka K: Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. Cancer Chemother Pharmacol. 2003 Feb;51(2):119-26. Epub 2002 Nov 20. [PubMed:12647012]
  2. Wei HL, Yao XJ, Li YN, Wang P, Zhao HS, Bai DC, Peng X, Ma LF: [Arsenic trioxide inhibits P-glycoprotein expression in multidrug-resistant human leukemia K562/ADM cell line that overexpresses mdr-1 gene and enhances their chemotherapeutic sensitivity]. Zhonghua Xue Ye Xue Za Zhi. 2003 Jan;24(1):28-31. [PubMed:12679007]
  3. Wei H, Su H, Bai D, Zhao H, Ge J, Wang B, Yao X, Ma L: Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene. Chin Med J (Engl). 2003 Nov;116(11):1644-8. [PubMed:14642128]
  4. Kimura A, Ishida Y, Wada T, Yokoyama H, Mukaida N, Kondo T: MRP-1 expression levels determine strain-specific susceptibility to sodium arsenic-induced renal injury between C57BL/6 and BALB/c mice. Toxicol Appl Pharmacol. 2005 Feb 15;203(1):53-61. [PubMed:15694464]
  5. Cronin CJ, Mendel JE, Mukhtar S, Kim YM, Stirbl RC, Bruck J, Sternberg PW: An automated system for measuring parameters of nematode sinusoidal movement. BMC Genet. 2005 Feb 7;6:5. [PubMed:15698479]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:54